News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 193–204 of 243 stories
Funding & Grants18 Sept 2026

Big Picture Bio Emerges from Stealth with €2.55m to Develop AI-Designed Cancer Drug Combinations

Big Picture Bio has emerged from stealth with €2.55 million (£2.2 million) in combined funding to develop AI-designed combination therapies for cancer. The round comprises a €1.75 million pre-seed co-led by Kadmos Capital and Exceptional Ventures, alongside €815k in non-dilutive support from Innovate UK's Investor Partnerships Programme. Founded by former Deep Science Ventures leaders Dr Kerstin Papenfuss and Dr Mark Hammond, the company has built a generative "world model" simulating tumour, immune cell and tissue interactions to predict which drug combinations and sequences are most likely to overcome cancer resistance, and will use the funding to move its first designed combinations from computational models into the lab.

Upperton Secures MHRA Approval for New Sterile Manufacturing Facility

Upperton has secured MHRA approval to bring its new Annex 1-aligned sterile manufacturing facility at Trent Gateway, Nottingham, within the scope of its existing MIA(IMP) licence, allowing it to begin GMP manufacture of sterile investigational medicinal products. The 7,000 sq ft facility, designed for small-scale aseptic and terminally sterilised drug product manufacture, sits alongside Upperton's existing 50,000 sq ft development and clinical manufacturing site, extending its offering to include sterile fill-finish for early-phase clinical programmes.

Croda Opens Global Biotechnology Centre at Sci-Tech Daresbury

Croda International has officially opened new biotechnology R&D laboratories at Sci-Tech Daresbury, designating the site its global centre for biotechnology research. The facility, formally opened by Minister for Reindustrialisation Blair McDougall MP and Liverpool City Region Mayor Steve Rotheram, is expected to support future job creation both at Daresbury and Croda's other four UK sites, and has already produced KeraBio K31, a biotech-derived keratin ingredient now being commercialised globally.

Funding & Grants16 Sept 2026

CrystecPharma Secures NPIF II Loan to Scale Ahead of Equity Round

CrystecPharma has secured a loan from NPIF II – Mercia Debt Finance, part of the Northern Powerhouse Investment Fund II, to scale its operations ahead of a planned equity investment round. The Bradford-founded pharmaceutical technology company, which uses supercritical fluid processing to engineer drug crystals and particles for inhaled and stabilised medicines, increased revenue by almost 80% in 2025 and expects a further 50% rise this year. The funding will support capacity growth as co-founders Paul Thorning and Qun Shao move from their academic roles at the University of Bradford to focus on the business full-time.

Funding & Grants16 Sept 2026

Chemify Secures £22m in Grants, Extends Series B to £51.9m

Chemify has received £22 million in grants from Scottish Enterprise and the UK Government to build a second-generation Chemifarm and become what it calls the first "Chemistry Hyperscaler." The grant sits alongside an extension of Chemify's Series B to £51.9 million, taking total funding secured to more than £110 million, and will support a new global headquarters at the University of Glasgow's Health Innovation Hub in Govan. The expansion is expected to grow Chemify's Scottish workforce from 152 to around 450 over three years, creating up to 300 jobs.

Avacta Reports Clinical Proof of Mechanism for AVA6103 in FOCUS-01 Trial

Avacta has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, in the Phase 1 FOCUS-01 trial. Across the first three dose levels in 19 patients, AVA6103 showed a clean safety profile even at a payload dose 50% above the maximum tolerated dose of conventional exatecan, with pharmacokinetic data closely matching preclinical predictions, and a head-to-head preclinical study found it produced deeper, more durable tumour responses than the marketed ADC Enhertu®. First efficacy data from the trial is expected in H1 2027.

ProAxsis Launches Updated Active Proteinase 3 Immunoassay

ProAxsis has launched an updated version of its ProteaseTag® Active Proteinase 3 Immunoassay (PA008-RUO), a research-use assay for measuring active Proteinase 3 in sputum samples. The update improves sensitivity to detect lower levels of the biomarker, following a similar upgrade to its Active Neutrophil Elastase Immunoassay last year, with an update to its Cathepsin G assay expected later in 2026.

Ori Biotech Signs 10-Year, $120m Partnership for Commercial Cell Therapy Manufacturing

Ori Biotech has signed a strategic collaboration with an undisclosed biopharmaceutical company to integrate its IRO® platform into a commercial autologous cell therapy manufacturing process, in a deal valued at up to $120 million in services, milestones, equipment and consumable purchases over 10 years. The partners will work to demonstrate comparability of the IRO process to the partner's existing commercial manufacturing process, aiming to reduce batch-to-batch variability, operator touch time and cost while expanding patient access. IRO has now signed 23 partners since its 2024 launch and reached a milestone in May 2026 with the first patient dosed with a therapy manufactured on the platform and released under GMP.

Funding & Grants15 Sept 2026

Magnitude Biosciences Raises £1.3m to Scale VivoScan Drug Discovery Platform

Magnitude Biosciences has raised £1.3 million to scale VivoScan, its high-throughput in vivo drug discovery platform built on C. elegans whole-organism screening. Northstar Ventures led the round through its North East Spinout Inspire Fund, North East Innovation Fund and EIS Growth Fund, joined by Maven's regional funds and new angel investors, with the raise also unlocking a further £217,000 Innovate UK Investor Partnership grant. The company plans to use the funding to expand commercial work with pharmaceutical clients, invest in automation, and grow its team.